BAKER BROS. ADVISORS LP Q4 2020 Filing
Filed February 16, 2021
Portfolio Value
$26.5B
Holdings
126
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (126 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Constellation Pharmaceuticals, Inc. | 114,735 | $3.3B | 12.45% | |
| 102 | LEGNLegend Biotech Corporation | 115,626 | $3.3B | 12.27% | |
| 103 | NGMUSDNGM Biopharmaceuticals, Inc. | 106,616 | $3.2B | 12.17% | |
| 104 | —Chiasma, Inc. | 742,133 | $3.2B | 12.16% | |
| 105 | AKROAkero Therapeutics, Inc. | 118,378 | $3.1B | 11.51% | |
| 106 | XLRNAcceleron Pharma Inc. | 22,430 | $2.9B | 10.81% | |
| 107 | —Dicerna Pharmaceuticals, Inc. | 102,121 | $2.3B | 8.48% | |
| 108 | INZYInozyme Pharma, Inc. | 106,999 | $2.2B | 8.32% | |
| 109 | OVIDOvid Therapeutics Inc. | 955,690 | $2.2B | 8.32% | |
| 110 | VKTXViking Therapeutics, Inc. | 363,980 | $2.0B | 7.72% | |
| 111 | RCUSArcus Biosciences, Inc. | 72,709 | $1.9B | 7.11% | |
| 112 | ORTXUSDOrchard Therapeutics plc | 332,502 | $1.4B | 5.41% | |
| 113 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $1.3B | 4.74% | |
| 114 | —Molecular Templates, Inc. | 133,833 | $1.3B | 4.74% | |
| 115 | OYSTOyster Point Pharma, Inc. | 61,424 | $1.2B | 4.36% | |
| 116 | GLPGGalapagos NV | 11,180 | $1.1B | 4.17% | |
| 117 | INFIQInfinity Pharmaceuticals, Inc. | 522,360 | $1.1B | 4.17% | |
| 118 | —Evofem Biosciences, Inc. | 411,396 | $991.0M | 3.73% | |
| 119 | —Affimed N.V. | 164,605 | $958.0M | 3.61% | |
| 120 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $879.0M | 3.31% | |
| 121 | KZRKezar Life Sciences, Inc. | 139,676 | $729.0M | 2.75% | |
| 122 | —Adamas Pharmaceuticals, Inc. | 147,996 | $641.0M | 2.41% | |
| 123 | GLMDGalmed Pharmaceuticals Ltd. | 184,927 | $575.0M | 2.17% | |
| 124 | QUREuniQure N.V. | 6,740 | $244.0M | 0.92% | |
| 125 | —Sunesis Pharmaceuticals, Inc. | 53,066 | $106.0M | 0.40% | |
| 126 | GNFTYGenfit SA | 14,720 | $71.0M | 0.27% |
PreviousPage 2 of 2